We are so proud to see Dr. Hans Hammers’s clinical trial of RADVAX selected for presentation at ASCO GU 2020. ASCO is the American Society of Clinical Oncology, and ASCO GU focuses on genitourinary cancers.

RADVAX combines SBRT with immunotherapy. This clinical trial showed that high-dose radiation added to immunotherapy can help more patients respond to immunotherapy. Using SBRT to inflame tumors can help the immune system recognize the tumor and therefore increases the response rate to immunotherapy. Higher response rates show that radiation is helping turn some people whose cancer would not respond to immunotherapy (non-responders) into responders.

The encouraging results for kidney cancer patients from this preliminary trial led to the selection of Dr. Hans Hammers and RADVAX for a presentation at ASCO.  

This trial was 100% patient and community funded through the grassroots efforts of Ralph and Brenda Knapp and KidneyCAN.

After impressive response rates, Bristol Myers Squibb has funded this SBRT and immunotherapy combination for continued research, which we hope to see translate quickly to clinical use. Ralph was one of the first patients to receive RADVAX and is pictured here with his wife Brenda and Dr. Hammers. 

Ralph and Brenda Knapp with Dr. Hans Hammers

You can check out Dr. Hammers’s ASCO GU abstract here, but do follow us on Facebook and Twitter to see our live updates of the event this week!

 

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer

Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer

Deb Beyhan is the Patient Legislative Advocate for KidneyCAN. She was diagnosed with stage IV kidney cancer in 2016 at the age of 53. Deb lives outside of Atlanta, GA, with her husband.    For this month's Community Spotlight, we want to tell you about a member of our volunteer team, Deb Beyhan....

DISTRICT DAYS 2022 →

SPRING ADVOCACY DAYS 2022 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

District Days: Asking Congress to Fund Kidney Cancer Research

District Days: Asking Congress to Fund Kidney Cancer Research

On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event and how you can help fund...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING YOUR CARE TEAM

TREATMENT & TRIAL OPTIONS

LIVING WELL WITH KIDNEY CANCER

CLINICAL TRIALS →

IMMUNOTHERAPY →

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

The 2022 Kidney Cancer Research Summit

The 2022 Kidney Cancer Research Summit

Dr. Laurence Albiges (Institut Gustave Roussy) presents on the microbiome at KCRS22. The microbiome has now been recognized as one of the emerging hallmarks and enabling characteristics of cancer. KidneyCAN hosted the 4th Annual Kidney Cancer Research Summit on October 6-7, 2022  live in...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Rock the Run for Kidney Cancer Research Funding

Rock the Run for Kidney Cancer Research Funding

KidneyCAN had the first ever Rock the Run 5k fundraiser in October 2022. This is part of the group of KCRS22 attendees who walked and ran with us at dawn before the second conference day began. KidneyCAN is proud to share the results of the first annual Rock the Run 5K fundraiser. Our Purpose...